Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes-Reference-Cited by-同舟云学术

Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes

Published:2024-03-06 Issue:3 Volume:28 Page:291-299
ISSN:1177-1062
Container-title:Molecular Diagnosis & Therapy
language:en
Short-container-title:Mol Diagn Ther

Author:

Nguyen Hanh^ORCID,Hird Kathryn,Cardaci Joe,Smith Steven,Lenzo Nat P.

Funder

The University of Notre Dame Australia

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40291-024-00699-w.pdf

Reference29 articles.

1. American Society of Clinical Oncology (ASCO). Prostate Cancer: Statistics. https://www.cancer.net/cancer-types/prostate-cancer/statistics. Accessed 6 Apr 2023.

2. Sharma R. The burden of prostate cancer is associated with human development index: evidence from 87 countries, 1990–2016. EPMA J. 2019;10(2):137–52. https://doi.org/10.1007/s13167-019-00169-y.

3. Seifert R, Alberts IL, Afshar-Oromieh A, Rahbar K. Prostate cancer theranostics: PSMA targeted therapy. PET Clin. 2021;16(3):391–6. https://doi.org/10.1016/j.cpet.2021.03.004.

4. O’Dwyer E, Bodei L, Morris MJ. The role of theranostics in prostate cancer. Sem Radiat Oncol. 2021;31(1):71–82. https://doi.org/10.1016/j.semradonc.2020.07.004.

5. Harris AE, Metzler VM, Lothion-Roy J, et al. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Review. Front Endocrinol. 2022. https://doi.org/10.3389/fendo.2022.1006101.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer;Cancers;2024-08-31

2. Monoclonal Antibody Therapies in Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

3. PSMA-based therapeutics for prostate cancer;Expert Opinion on Pharmacotherapy;2024-07-02